Status:
UNKNOWN
Cohort Study Assessing the Treatment Strategy for High-Risk Myelodysplastic Syndromes in Patients Under 70
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Myelodysplastic Syndromes
Eligibility:
All Genders
18-70 years
Brief Summary
Myelodysplastic syndromes (MDS) are bone marrow malignant diseases resulting in ineffective haematopoiesis and subsequently, blood cell count decrease. Patients have anaemia responsible of fatigue and...
Detailed Description
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders due to qualitative defects of the hematopoietic stem cell, resulting in uneffective hematopoiesis, dysplasia of one or mo...
Eligibility Criteria
Inclusion
- Age\> 18 years old and \<70 years old
- MDS-HR defined by an intermediate or high IPSS score (≥ 1.5), or IPSS revised ≥ to 4.5.
- Diagnosis affirmed by 2 myelograms at least 1 month apart or 1 single characteristic myelogram if prior haematological abnormalities on complete blood count present for more than 6 months
- Free informed consent signed by the patient and the investigator (at the latest on the day of inclusion and before any examination required by the study)
- Affiliate or beneficiary of a social security system
Exclusion
- Age ≥ 70 years
- MDS-LR defined by a low IPSS score (\<1.5), or revised IPSS \<4.5
- Women of childbearing potential not using contraception, pregnant or breastfeeding
- Not affiliated to the Social Security system
Key Trial Info
Start Date :
October 9 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2024
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT05367583
Start Date
October 9 2013
End Date
October 1 2024
Last Update
July 8 2022
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
CH AGEN
Agen, France
2
Ch Bayonne
Bayonne, France
3
Chu de Bordeaux
Bordeaux, France
4
Institut Bergonie
Bordeaux, France